New titles will meet growing demand for gold open access, and build on the Current Opinion legacy of editorial excellence, high-impact and global reach
AMSTERDAM, June 18, 2019 /PRNewswire/ -- Elsevier, the information analytics business specializing in science and health, continues to expand its offering of gold open access titles with the launch of Current Research, a series of primary research titles spanning the life and physical sciences. Current Research will serve as a companion to the highly-regarded Current Opinion review journals.
Current Research marks the creation of the Current Opinion and Research (CO+RE) suite of journals and will publish original research and short communications across the life and physical sciences, including research from food science to green and sustainable chemistry topics.
"The launch of our Current Research titles marks an important milestone in Elsevier's continued growth in open access (OA) publishing," said Louise Curtis, Senior Vice President at Elsevier. "We already publish many high-quality primary research journals that offer authors the choice to publish OA, whether under the hybrid model or gold OA model. The Current Research portfolio is an exciting addition to our current programme of over 270 gold OA titles."
Seven new titles in Biotechnology, Food Science, Immunology, Pharmacology and Drug Discovery, Physiology, Structural Biology and Toxicology have already launched with more titles in development. Each CO+RE journal will leverage the Current Opinion legacy of editorial excellence, high-impact, and global reach—to ensure they are a widely-read resource and become an integral part of a researchers' workflow.
"A big advantage of gold OA is that you can access the full text all the time, wherever you are," said Atanas G. Atanasov, PhD, and Editor-in-Chief of Current Research in Biotechnology. "The CO+RE suite will use the long-standing tradition of high-quality output of the CO journals, and the global outreach offered through the gold OA publishing model of the RE journals. In a rapidly-developing field like biotechnology, visibility is critical."
Expert Editors and prestigious Editorial Boards will bring a depth of knowledge and experience to all Current Research titles. Submission and peer review will be fast, and publication of final manuscripts will be instantaneous. Articles published in Current Research journals will enjoy the high visibility and maximum exposure of an industry leading platform that reaches a global audience.
"Current Research is a bold initiative and further reinforces Elsevier's investment in Open Access and Open Science," said Philippe Terheggen, Managing Director for STM Journals, Elsevier. "Demonstrating that we continue to work closely and listen to our research communities in order to provide them with the best options for publication."
About open access at Elsevier
Elsevier is the fastest growing open access publisher. Researchers have the option to publish open access and make their articles permanently available immediately in almost all of our journals, at a price below industry average while delivering above-average quality. The green OA option is also available across all Elsevier journals. We support over 600 research institutions worldwide in building their own open access programs with Digital Commons. We encourage authors to share their work, including prior to publication on platforms of their choice such as SSRN. Additionally, we make it easier to discover OA content in Scopus, where you can search, browse and set up alerts for over 8 million open access articles. Learn more about how Elsevier supports open access here: www.elsevier.com/about/open-science/open-access/supporting-open-access.
Elsevier is a global information analytics business that helps scientists and clinicians to find new answers, reshape human knowledge, and tackle the most urgent human crises. For 140 years, we have partnered with the research world to curate and verify scientific knowledge. Today, we're committed to bringing that rigor to a new generation of platforms. Elsevier provides digital solutions and tools in the areas of strategic research management, R&D performance, clinical decision support, and professional education; including ScienceDirect, Scopus, SciVal, ClinicalKey and Sherpath. Elsevier publishes over 2,500 digitized journals, including The Lancet and Cell, 39,000 e-book titles and many iconic reference works, including Gray's Anatomy. Elsevier is part of RELX Group, a global provider of information and analytics for professionals and business customers across industries. www.elsevier.com
Jonathan Davis, Communications Officer